Clinical Scorecard: Clinical Presentation of Graves Disease in the Context of Autoimmune Polyglandular Syndrome Versus Isolated Cases: Insights from the GRAPHE Study
At a Glance
Category
Detail
Condition
Graves disease (GD), an autoimmune hyperthyroidism often accompanied by Graves orbitopathy (GO), occurring either as isolated disease or part of autoimmune polyglandular syndrome (APS).
Key Mechanisms
Autoantibodies to TSH receptor (TRAb) stimulate thyroid hormone synthesis and thyroid growth; TRAb also affect orbital fibroblasts causing GO.
Target Population
Patients diagnosed with Graves disease, including those with isolated GD and those with GD as part of APS.
Care Setting
Outpatient endocrinology, nuclear medicine, and clinical surgery clinics following guideline-based management.
Key Highlights
Isolated GD patients more frequently exhibit Graves orbitopathy and have a more severe clinical course than GD patients with APS.
No significant differences at disease onset in gender distribution, thyroid hormone levels (fT4, fT3), TRAb titers, or thyroid volume among isolated GD and APS groups.
Isolated GD patients have higher rates and earlier timing of definitive therapy (surgery or radioiodine) compared to GD patients with APS.
Guideline-Based Recommendations
Diagnosis
Diagnosis based on clinical features of hyperthyroidism, measurement of fT4, fT3, TSH, and TRAb levels.
Assessment for Graves orbitopathy according to European Group on Graves’ Orbitopathy (EUGOGO) guidelines.
Screening for other autoimmune endocrinopathies to identify APS in GD patients.
Management
First-line treatment with thionamides to inhibit thyroid hormone synthesis and achieve remission.
Definitive treatments (surgery or radioiodine) considered especially in moderate to severe GO or relapse after antithyroid drugs.
Management tailored according to presence of APS and severity of clinical presentation.
Monitoring & Follow-up
Regular follow-up with clinical and biochemical assessment to detect relapses and progression.
Periodic screening for additional autoimmune diseases in patients with GD to identify APS development.
Risks
High relapse rates (>50%) after antithyroid drug therapy necessitating definitive treatment.
More severe orbitopathy and earlier need for definitive therapy in isolated GD compared to GD with APS.
Potential transition from hyperthyroidism to hypothyroidism more frequent in GD patients with other autoimmune diseases.
Patient & Prescribing Data
567 patients with GD (77% women), including isolated GD and GD associated with APS.
Isolated GD patients more often require definitive therapy sooner than those with APS; antithyroid drugs remain first-line but relapse is common.
Clinical Best Practices
Use standardized diagnostic criteria including TRAb measurement and EUGOGO guidelines for GO assessment.
Screen GD patients for other autoimmune diseases to identify APS early.
Consider earlier definitive therapy in isolated GD patients due to more severe clinical course.
Follow patients longitudinally for disease progression, relapse, and development of additional autoimmune conditions.
by Elisa Gatta, Ilenia Pirola, Aurora Gotti, Micaela Fredi, Pietro Bellini, Francesco Dondi, Riccardo Morandi, Claudio Casella, Francesco Bertagna, Franco Franceschini, Mario Rotondi, Carlo Cappelli
Uptake will require “compelling evidence that these systems can reduce time and effort while at least maintaining, if not improving, diagnostic accuracy, making the cost of implementation and continued usage worthwhile.”
